Dabrafenib and Trametinib

Two targets in the same signalling pathway

Dabrafenib and trametinib are targeted medicines, also known as Tafinlar and Mekinist. Dabrafenib inhibits mutated BRAF; trametinib inhibits MEK, a later step in the MAPK pathway. In some melanomas this signalling chain promotes tumour-cell proliferation. Blocking it at two points provides the rationale for the combination.

They are not immunotherapies and are not conventional cytotoxic chemotherapy. Their use requires a relevant mutation documented in the tumour: a melanoma diagnosis alone is insufficient. Target selectivity does not mean no effects on healthy tissues or a guaranteed response. Targeted treatment also requires monitoring and can cause important adverse effects.

The medicines have complementary roles but different instructions and safety profiles. The combination must be the prescribed one: independently substituting another BRAF or MEK inhibitor for a component is inappropriate.

Sources for this section: EMA — Tafinlar: indications, product information and leaflet; EMA — Mekinist: indications, product information and leaflet.

European indications and access in Italy

The combination is an established option for unresectable or metastatic melanoma with a BRAF V600 mutation. It also has an adjuvant indication in completely resected BRAF V600 stage III melanoma. In the updated EMA documentation consulted, melanoma indications include adults and adolescents aged 12 or older; adolescent assessment and dosing require specific expertise and cannot be inferred from adult regimens.

Authorisation does not mean everyone with the mutation should receive this pair, or that every use is automatically reimbursed under identical conditions in Italy. The centre checks the indication, AIFA criteria, any monitoring registries and alternatives. Age, stage and variant must be interpreted within current product information.

Using the same medicines before surgery or in a different combination is a separate question: an indication cannot be extended simply by analogy.

Sources for this section: EMA — Tafinlar: indications, product information and leaflet; EMA — Mekinist: indications, product information and leaflet; AIFA — Reimbursement and pricing.

BRAF V600E, V600K and interpreting the report

BRAF V600 must be confirmed with a validated test before treatment. Material may come from the melanoma or a metastasis, depending on availability and laboratory assessment. The report must specify the variant: BRAF V600E and V600K are not interchangeable with any gene alteration, and non-V600 mutations require different considerations.

Specimen quality and what the method can detect matter. If a result cannot be interpreted, the team may request further analyses; it must not automatically be equated with a negative result. A tumour mutation alone does not imply inherited predisposition.

Even when the target is present, treatment selection remains a clinical decision. In adjuvant decisions, variant-specific evidence and updated recommendations are especially important: the breadth of a regulatory authorisation and the preference expressed in a guideline do not necessarily coincide.

Sources for this section: ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025); NCBI ClinVar — BRAF c.1799T>A, p.Val600Glu; EMA — Tafinlar: current product information and patient leaflet.

The early trials: BREAK-3 and METRIC

In 2012, BREAK-3 compared dabrafenib alone with dacarbazine in 250 patients with advanced BRAF V600E melanoma. The initial publication reported median progression-free survival of 5.1 versus 2.7 months. The finding contributed to drug development, but describes monotherapy and a historical chemotherapy comparison.

That same year, METRIC assessed trametinib alone against chemotherapy in 322 patients with advanced BRAF V600E or V600K melanoma. Median progression-free survival was 4.8 versus 1.5 months. These studies cannot be compared as though they had assigned the same patients to the two molecules.

Retaining these milestones helps explain how treatment evolved. It does not justify describing the medicines today as newly announced, or using monotherapy results to estimate the benefit of the current combination.

Sources for this section: Hauschild et al. — BREAK-3, phase 3 (2012); Flaherty et al. — METRIC, phase 3 (2012).

COMBI-d and COMBI-v: combination treatment

COMBI-d and COMBI-v compared the pair with BRAF inhibition alone, using dabrafenib and vemurafenib respectively as controls. Their contribution differs from the earliest trials: they directly concern dual BRAF/MEK inhibition and its role in advanced disease.

The analysis published in 2019 on five-year outcomes among combination-treated patients documents that some can achieve prolonged control. It does not mean every response lasts years, or that a complete radiological response automatically equals cure. Baseline disease characteristics and the patient’s condition affect interpretation.

These trials also have defined comparators and inclusion criteria. They do not alone establish the best initial treatment against every modern immunotherapy regimen. Discussion of sequence requires dedicated evidence and individual assessment.

Sources for this section: Robert et al. — COMBI-d/COMBI-v, five-year outcomes (2019); ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025).

COMBI-AD: after complete resection

In the adjuvant setting, treatment does not necessarily target a visible remaining mass: its purpose is to lower recurrence risk after surgery. COMBI-AD studied dabrafenib and trametinib against placebo in 870 patients with completely resected stage III melanoma and a BRAF V600E or V600K mutation.

The final 2024 analysis confirmed benefit for recurrence outcomes; overall survival in the full population did not reach the specified statistical significance. This distinction must remain explicit: reducing recurrences and demonstrating an overall-survival advantage are not the same outcome.

Selection requires balancing baseline risk, expected benefit, toxicity and alternatives. Variant-specific analyses need cautious interpretation alongside guidelines; identical benefit cannot be promised to every subgroup. Follow-up remains necessary after treatment has ended.

Sources for this section: Long et al. — COMBI-AD, final results (2024); ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025).

Brain metastases: interpreting COMBI-MB correctly

COMBI-MB is a phase II study with several cohorts, not a randomised comparison against every other treatment. In the main cohort of 76 patients with BRAF V600E, asymptomatic brain metastases and no previous local brain therapy, an intracranial response was observed in 58% of participants. Duration of control remained an important limitation.

This figure must not automatically be extended to symptomatic patients, those receiving corticosteroids, people with a different variant or other clinical circumstances. Older percentages for dabrafenib alone and particular subgroups do not describe the combination in all patients.

Management requires integration with neuro-oncology, surgical and radiation assessments where relevant. A sudden severe headache, neurological deficit or seizure requires urgent care. Systemic treatment does not automatically remove the need for local treatment or brain imaging follow-up.

Sources for this section: Davies et al. — COMBI-MB, phase 2, brain metastases (2017); ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025).

Targeted treatment or immunotherapy: sequencing matters

Having BRAF V600 does not mean targeted treatment must always come first. DREAMseq compared two sequences: nivolumab–ipilimumab immunotherapy followed, at progression, by dabrafenib–trametinib, or the reverse order. In the study population, survival favoured the sequence starting with immunotherapy.

This is clinically important information, but not a rule to apply without considering the individual case. Symptoms, growth rate, need for prompt control, brain metastases, overall health and ability to receive immunotherapy can alter the balance. Not every trial participant reaches the planned second treatment.

A useful question for the centre is therefore: why is this sequence appropriate for me, and what criteria will trigger reassessment? An effective treatment should not be stopped because of a comparison read online.

Sources for this section: DREAMseq — Randomized treatment-sequence trial (2022/2023); ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025).

Fever: a written plan before starting

Fever is a relevant effect of the combination and can recur. It may be accompanied by chills, dehydration, low blood pressure and kidney problems; it should not be dismissed as an inevitable nuisance. A treatment reaction must also be distinguished from infection or other causes.

Before starting, request a written plan specifying temperatures and symptoms to report, contact details, any interruptions and the centre’s restart instructions. The leaflet advises contacting the team immediately for fever of 38°C or higher or a feeling that fever is starting. Do not wait for the next scheduled visit.

Do not make up doses, alter the calendar or independently restart after an interruption. The doctor determines how to manage the episode and whether investigations are needed. Severe illness, confusion, fainting or breathlessness require urgent assessment.

Sources for this section: EMA — Tafinlar: current product information and patient leaflet; MedlinePlus — Dabrafenib: patient information (US context).

Heart, eyes, lungs and other warning signs

The safety plan includes cardiac function and other tests according to individual circumstances. New breathlessness, swelling, palpitations or reduced exercise tolerance should be reported. Vision changes, eye pain or redness need prompt attention rather than simply waiting for them to disappear.

Lung problems, bleeding and other serious events are also possible. Persistent cough, difficulty breathing, blood in stools or vomit and substantial pain warrant assessment. These examples are not a complete list and cannot support self-diagnosis: a symptom can have many causes.

The team determines monitoring frequency, specialist assessments and treatment modifications. Early reporting does not necessarily mean treatment must be abandoned; it allows safety to be assessed. In emergencies, bring the medication list and state when the latest doses were taken.

Sources for this section: EMA — Mekinist: current product information and patient leaflet; EMA — Mekinist: indications, product information and leaflet.

Skin, blood glucose and pre-existing conditions

Dermatological checks assess rashes and new lesions, including skin carcinomas and keratoacanthomas associated with BRAF inhibitors. Combination treatment changes some risks compared with monotherapy but does not eliminate skin surveillance. A new lesion should not automatically be considered either harmless or melanoma recurrence.

Report diabetes, kidney or liver problems and every pre-existing condition. Blood glucose may require particular attention. Also disclose known G6PD deficiency: US prescribing information flags a potential haemolysis risk in this situation, requiring clinical assessment rather than an automatic diagnosis.

Sun protection and skin observation remain part of care. Photographs and notes can help describe changes to the doctor, but do not replace an examination when a new lesion or substantial rash appears.

Sources for this section: DailyMed — Tafinlar: US prescribing information; MedlinePlus — Dabrafenib: patient information (US context); EMA — Tafinlar: current product information and patient leaflet.

Interactions and correct administration

Provide a complete list of prescriptions, over-the-counter medicines, supplements and herbal products. Dabrafenib can interact through enzyme systems that change its exposure or that of other treatments. This includes medicines taken for conditions unrelated to cancer; the hospital pharmacist can help reconcile the medication list.

Instructions about meals, missed doses and vomiting must match the prescribed formulation and current leaflet. Do not automatically transfer instructions between capsules, tablets or different formulations. If swallowing is difficult, ask before opening, crushing or otherwise altering the medicine.

Do not independently stop another medicine because of an interaction concern, or introduce “natural” products without reporting them. An updated list shared with the general practitioner reduces the risk of conflicting instructions.

Sources for this section: MedlinePlus — Dabrafenib: patient information (US context); EMA — Tafinlar: current product information and patient leaflet; EMA — Mekinist: current product information and patient leaflet.

Pregnancy, contraception and fertility

Before treatment, discuss possible pregnancy, contraception, breastfeeding and plans for children. The medicines can harm a fetus, and interactions can affect the reliability of some contraceptive methods. The centre must explain precautions and how long they remain necessary after the last dose according to the products used.

Do not assume instructions are identical for both medicines or that stopping treatment immediately makes pregnancy safe. If pregnancy is suspected during treatment, contact the team promptly. Breastfeeding should be discussed before starting rather than managed using generic information.

Possible effects on fertility deserve an early conversation while preservation options can still be considered. Reproductive wishes are part of quality of life and should be addressed alongside cancer-treatment priorities.

Sources for this section: MedlinePlus — Dabrafenib: patient information (US context); DailyMed — Tafinlar: US prescribing information; EMA — Mekinist: current product information and patient leaflet.

Resistance and strategies still under investigation

Dual inhibition can delay progression but cannot prevent every resistance mechanism. If disease progresses, the team reassesses lesion distribution, symptoms, previous treatments and subsequent options, including local or systemic approaches. An imaging change must be interpreted within the overall pathway.

Trials of new sequences, immunotherapy combinations or perioperative uses require individual assessment. Approval of the components is not enough: a new combination can have different benefits and risks. Standard use of the pair and experimental use can therefore coexist in different settings.

For a trial proposal, ask for the protocol identifier, phase, objective, eligibility criteria, alternatives and adverse-effect arrangements. Participation does not guarantee personal benefit. An informed decision requires discussion and must not involve independently abandoning appropriate care.

Sources for this section: ESMO — Cutaneous melanoma: Clinical Practice Guideline (2024/2025); DREAMseq — Randomized treatment-sequence trial (2022/2023); National Cancer Institute — Participate in Cancer Treatment Trials.

Sources and update

Editorial revision and source consultation: 17 October 2026. Study dates distinguish current evidence from historical documents. This date does not certify specialist clinical review.